Non-clinical safety of novel cross-linked chondroitin sulfate (SI-449) as an anti-adhesion barrier for abdominal and pelvic surgeries
Journal of Biomaterials Applications · 2026
DOI: 10.1177/08853282261432825 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biomaterials Applications, 2026. Verfasst von Ayako Shiraki und 8 weiteren Autor:innen. Beteiligte Einrichtung: Central Research Laboratory, Research & Development Division, Seikagaku Corporation, Higashiyamato-shi, Tokyo, Japan. Hauptthemen laut MEDLINE: Chondroitin Sulfates, Pelvis, Abdomen, Biocompatible Materials. Die Arbeit nennt 54 Literaturangaben. Gefördert von: Seikagaku Corporation.
Abstract (Originalsprache)
Postoperative adhesions result from abnormal tissue repair and most frequently occur in patients following abdominal and pelvic surgeries. Prevention of adhesion formation, including the use of anti-adhesion barriers during surgery, is considered the most effective clinical strategy for postoperative adhesions. However, no commercial product is commonly used worldwide because of its insufficient efficacy, complexity, and difficulty of use. We developed a new anti-adhesion barrier using novel biomaterial (SI-449), a cross-linked chondroitin sulfate, in an easy-to-apply powder form. Our previous study using animal models showed that the anti-adhesion efficacy of SI-449 was superior to that of an existing product. In this study, the safety of SI-449 was evaluated based on the results of systemic toxicity tests in rats after intraperitoneal application and a wound healing test in laparotomized rats to mimic its clinical use in abdominal and pelvic surgeries. In the systemic toxicity test, minimal and transient hematological changes and muscular regeneration in the abdominal wall and ileum were observed and were considered to be related to systemic toxicity or local irritation due to SI-449. However, these findings were within the safety margin and not associated with serious toxicity. Other changes were considered physiological reactions to SI-449 or its degradants. In the wound healing test, SI-449 was found to have no effect on the healing of the incisional abdominal wall. In conclusion, the non-clinical safety of SI-449 was confirmed, and this novel biomaterial is expected to be used as an anti-adhesion barrier in abdominal and pelvic surgeries.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Central Research Laboratory, Research & Development Division, Seikagaku Corporation, Higashiyamato-shi, Tokyo, Japan.
- R&D Strategy, Research & Development Division, Seikagaku Corporation, Chiyoda-ku, Tokyo, Japan.
ORCID-Profile: Ayako Shiraki, Shino Ito, Dai Muramatsu, Tomomi Miyahara, Keiji Yoshioka
Förderung
- Seikagaku Corporation
Zitieren
APA
Shiraki, A., Ito, S., Muramatsu, D., Sasaki, T., Otsuka, A., Miyahara, T., Takahashi, K., Yoshioka, K., & Suehiro, M. (2026). Non-clinical safety of novel cross-linked chondroitin sulfate (SI-449) as an anti-adhesion barrier for abdominal and pelvic surgeries. Journal of Biomaterials Applications. https://doi.org/10.1177/08853282261432825
Vancouver
Shiraki A, Ito S, Muramatsu D, Sasaki T, Otsuka A, Miyahara T, et al. Non-clinical safety of novel cross-linked chondroitin sulfate (SI-449) as an anti-adhesion barrier for abdominal and pelvic surgeries. Journal of Biomaterials Applications. 2026. doi:10.1177/08853282261432825
BibTeX
@article{Shiraki2026,
author = {Shiraki, Ayako and Ito, Shino and Muramatsu, Dai and Sasaki, Tomoki and Otsuka, Akira and Miyahara, Tomomi and Takahashi, Katsuya and Yoshioka, Keiji and Suehiro, Miki},
title = {Non-clinical safety of novel cross-linked chondroitin sulfate (SI-449) as an anti-adhesion barrier for abdominal and pelvic surgeries},
journal = {Journal of Biomaterials Applications},
year = {2026},
doi = {10.1177/08853282261432825}
}
EUVIMED